Blocking the movement of cells from the bone marrow by inhibiting the CXCL12/CXCR4/CXCR7 signaling axis is a potential strategy for treating endometriosis, a recent study done in mice suggests.

The study, titled CXCR4 or CXCR7 antagonists treat endometriosis by reducing bone marrow cell trafficking, was published in theJournal of Cellular and Molecular Medicine.

Bone marrow-derived cells (BMDCs) play important roles in the normal functioning of the endometrium. For instance, stem cells from the bone marrow are involved in endometrial regeneration. But BMDCs also are involved in the formation of lesions in endometriosis.

The movement of BMDCs to uterine tissue whether for normal physiological reasons or as part of disease development is driven in large part by the signaling protein CXCL12. It acts through two protein receptors: CXCR4 and CXCR7. This CXCL12/CXCR4/CXCR7 signaling axis has been shown to be overactive in women with endometriosis.

Given the central role of the CXCL12/CXCR4/CXCR7 axis on BMDCs trafficking and in the pathogenesis [development] of endometriosis, we hypothesized that blocking CXCR4 or CXCR7 in endometriosis would inhibit the growth of endometriosis, the researchers said.

The scientists first used mouse models of endometriosis in which BMDCs were labeled with a fluorescent marker to confirm the presence of these cells in endometriotic lesions.

The BMDCs made up just over 10% of the total number of cells in lesions. Further, BMDCs that expressed CXCR4 represented about 4.4% of total lesion cells, while BMDCs expressing CXCR7 made up about 1.4%. CXCL12 also was highly expressed within the lesions.

The researchers then pharmacologically blocked each of the receptors, using Plerixafor (AMD3100) against CXCR4, and CCX771 against CXCR7. Plerixafor is used in stem cell transplants given to treat certain types of blood cancer. CCX771 is a small molecule without currently approved clinical uses.

Both treatments significantly reduced the percentage of BMDCs in lesions, suggesting that blocking this signaling axis did indeed stop the movement of these cells.

In addition, when either Plerixafor or CCX771 was given immediately after endometriosis establishment, the size of the endometriotic lesions was reduced by more than half compared with control mice. Blood vessel density also was significantly reduced, by about 40% for both receptors.

The treatments also reduced the expression of inflammatory signaling molecules known to be elevated in endometriosis, such as interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFalpha).

In a separate experiment to further test the treatments potential, Plerixafor and CCX771 were administered a few weeks after the endometriosis lesions developed. This more closely models the preexisting lesions found in humans at the time of endometriosis diagnosis, the researchers said.

The results were similar to those seen in the earlier model: there were significant decreases in lesion size by about 60% as well as in levels of inflammatory signaling molecules.

Notably, neither drug had any detectable effect on hormone cycling in the mice, demonstrating that the effects of these agents worked [through] a hormone independent pathway, the researchers said.

Based on the data, the researchers concluded that blocking the CXCL12/CXCR4/CXCR7 signaling axis may treat endometriosis. However, these results alone do not demonstrate that this effect is directly because of reduced BMDC recruitment. It would be equally plausible to postulate that the effect is due to blocking CXCL12/CXCR4/CXCR7 signaling in the endometrial cells themselves, not BMDCs, the investigators said.

To test this idea, the team established endometriosis models in mice that were engineered so that the cells in their uteruses could not make CXCL12. There were no detectable differences between these endometriosis lesions and lesions in mice that could make CXCL12 in their uteruses. Further, Plerixafor had no detectable effect on human endometrial cells taken from people with endometriosis and treated in a dish.

This suggests that the beneficial effect induced by blocking CXCL12/CXCR4/CXCR7 signaling is due to an effect on cells outside of the uterus. Due to their prevalence in lesions, this most likely means BMDCs, the researchers said.

Clinical use [of these therapies] will likely depend on side effect profile; the effects of prolonged use are not well characterized, the team said. They added that future studies evaluating such drugs safety profiles and off-target effects, particularly with long-term use, will be needed before these results can be translated into clinical application.

CXCR4 and CXCR7 antagonists are promising novel, nonhormonal therapies for endometriosis, the researchers concluded.

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

Total Posts: 146

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Tcnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Excerpt from:
Blocking Bone Marrow Cell Movement May Be Non-Hormonal Treatment... - Endometriosis News Today

Bone Marrow Stem Cells Comments Off on Blocking Bone Marrow Cell Movement May Be Non-Hormonal Treatment… – Endometriosis News Today | February 4th, 2020

Jack Chieh and Yinnie Wong with their baby boy, born last Friday (Chinese New Year). The couple donate her baby's cord blood to the cord blood bank at B.C. Womens Hospital & Health Centre.Handout

By Denise Ryan

Yinnie Wong and Jack Chiehs six-pound, 13-ounce baby boy as yet unnamed was born on an auspicious day, Jan. 24, Chinese New Year, and hes already doing good in the world.

Everyone was really happy, it is supposed to be a lucky day, said Wong.

Although the birth was a planned C-section, Wong had no control over the date hospital administrators chose for the birth. What she did have control over was the choice to donate her babys cord blood to thecord blood bank at B.C. Womens Hospital & Health Centre, which has just celebrated its fifth anniversary.

Cord blood is blood that is taken from the umbilical cord and placenta immediately after the birth of a healthy infant. Cord blood is rich in stem cells, and can be used to treat over 80 diseases, including leukemia.

According to Canadian Blood Services, ethnically diverse donors are especially needed because although Stats Canada data shows 67.7 per cent of Canadians consider their ethnic origin to be diverse, only 31 per cent of Canadians with blood in Canadas stem-cell registry are from ethnically diverse backgrounds.

Crystal Nguyen, 20, is a former B.C. Childrens Hospital patient whose life was saved by a stem-cell transplant from donated cord blood. Nguyen was first diagnosed with acute myeloid leukemia at age 12. After chemo, she went into remission for almost three years. Then the cancer returned. She was told she needed a bone-marrow transplant.

When I relapsed I was very confused, it was kind of surreal. The main thing about being told I needed the bone-marrow stem-cell transplant was confusion, fear and anxiety.

Nguyen is of Vietnamese descent and needed a match to survive. No one in her family was a match, nor was there a stem-cell match in the Canadian cord blood bank, but a match was found thanks to the Canadian Blood Services partnerships with 47 international blood banks.

I was told it came through the international cord blood bank from somewhere very far away, said Nguyen, who has been in remission since the transplant.

When she learned the stem-cell transplant had been successful, Nguyen, who is now studying to become a pediatric oncology nurse, said it felt too good to be true.

There was a lot of happiness, joy, excitement. Donating cord blood is such a simple way to save a life.

Although cord blood can be collected and stored for a fee by private companies and reserved for the donor familys use, cord blood donated through Canadian Blood Services is available free to the public whoever needs the match.

Wong didnt hesitate when her son was born. I felt like I wanted to do it if it helps someone in the public, and if it could save lives I would have been very happy to help another child, said Wong, who is a nurse at B.C. Womens hospital.

dryan@postmedia.com

View post:
Chinese New Year babys B.C. family gives gift of life in cord - The Province

Bone Marrow Stem Cells Comments Off on Chinese New Year babys B.C. family gives gift of life in cord – The Province | February 3rd, 2020

Kenneth Pettine's stem cell product to treat OA was tested on retired Navy SEALs

FORT COLLINS, CO / ACCESSWIRE / February 3, 2020 / Kenneth Pettine is proud to announce that his revolutionary mesenchymal stem cell product to treat osteoarthritis was recently tested on 33 former Navy SEALs (one is a medal of honor recipient).

Kenneth Pettine is co-founder of Paisley Laboratories and a co-developer of a bone marrow-derived mesenchymal stem cell active growth factor and exosome product that is anticipated to revolutionize regenerative medicine.

In this study, Extracellular Vesicle Isolate Product (EVIP) was injected into 33 retired Navy SEALs to assist with knee, shoulder, elbow, ankle, and wrist osteoarthritis. At three-month follow-up, the injection appeared both safe and effective, with improvements ranging from 40% to as high as 98%. The average improvement is over 70%.

"This is extremely promising and we are motivated to continue our clinical studies to improve the quality of life for patients," says Kenneth Pettine.

Kenneth Pettine notes in his study that over 50 million Americans require daily treatment for disability and pain associated with OA. Every year, over one million total hip and knee replacements are performed in the U.S. with direct costs of over $30 billion and indirect costs of over $200 billion, with these numbers expected to double in the next three years.

In addition to this trial, Kenneth Pettine has three additional clinical studies planned to evaluate his stem cell products to treat erectile dysfunction, chronic obstructive pulmonary disease (COPD), and chronic lower back pain from painful discs.

For more information, visit https://www.kenneth-pettine.com/

About Kenneth Pettine

Dr. Kenneth Pettine is a serial entrepreneur and published clinical researcher with over 30 years of experience as an orthopedic surgeon. He holds a medical degree from the University of Colorado School of Medicine and completed his master's degree in orthopedic surgery and residency at the Mayo Clinic in Rochester, Minnesota.

In 1991, Dr. Pettine founded the Rocky Mountain Associates in Orthopedic Medicine. Kenneth Pettine is also the founder of Paisley Laboratories and the co-founder of the Society for Ambulatory Spine Surgery. In addition, he co-invented the Prestige cervical artificial disc and the Maverick Artificial Disc. Dr. Pettine is the principal investigator of 18 FDA studies involving non-fusion implants, biologics, and stem cells. He holds the only two issued U.S. patents for performing stem cell joint and spinal injections and currently has 21 additional patents pending for bone marrow derived mesenchymal stem cell applications. Kenneth Pettine is also a philanthropist and currently has a scholarship program underway to help students fund their education.

For more information, visit https://www.kenneth-pettine.com/ or https://www.kennethpettinescholarship.com/

Contact

info@kenneth-pettine.com

https://www.kenneth-pettine.com/

SOURCE: Kenneth Pettine

View source version on accesswire.com: https://www.accesswire.com/574987/Dr-Kenneth-Pettine-Announces-Verification-of-Clinical-Safety-Trial

Link:
Dr. Kenneth Pettine Announces Verification of Clinical Safety Trial - Yahoo Finance

Bone Marrow Stem Cells Comments Off on Dr. Kenneth Pettine Announces Verification of Clinical Safety Trial – Yahoo Finance | February 3rd, 2020

Jack Chieh and Yinnie Wong with their baby boy, born last Friday (Chinese New Year). The couple donate her baby's cord blood to the cord blood bank at B.C. Womens Hospital & Health Centre.Handout

Yinnie Wong and Jack Chiehs six-pound, 13-ounce baby boy as yet unnamed was born on an auspicious day, Jan. 24, Chinese New Year, and hes already doing good in the world.

Everyone was really happy, it is supposed to be a lucky day, said Wong.

Although the birth was a planned C-section, Wong had no control over the date hospital administrators chose for the birth. What she did have control over was the choice to donate her babys cord blood to the cord blood bank at B.C. Womens Hospital & Health Centre, which has just celebrated its fifth anniversary.

Cord blood is blood that is taken from the umbilical cord and placenta immediately after the birth of a healthy infant. Cord blood is rich in stem cells, and can be used to treat over 80 diseases, including leukemia.

According to Canadian Blood Services, ethnically diverse donors are especially needed because although Stats Canada data shows 67.7 per cent of Canadians consider their ethnic origin to be diverse, only 31 per cent of Canadians with blood in Canadas stem-cell registry are from ethnically diverse backgrounds.

Crystal Nguyen, 20, is a former B.C. Childrens Hospital patient whose life was saved by a stem-cell transplant from donated cord blood. Nguyen was first diagnosed with acute myeloid leukemia at age 12. After chemo, she went into remission for almost three years. Then the cancer returned. She was told she needed a bone-marrow transplant.

Crystal Nguyen, now 20, was first diagnosed with acute myeloid leukemia at age 12. She found a stem-cell match for a needed bone-marrow transplant through the international cord blood bank.Handout

When I relapsed I was very confused, it was kind of surreal. The main thing about being told I needed the bone-marrow stem-cell transplant was confusion, fear and anxiety.

Nguyen is of Vietnamese descent and needed a match to survive. No one in her family was a match, nor was there a stem-cell match in the Canadian cord blood bank, but a match was found thanks to the Canadian Blood Services partnerships with 47 international blood banks.

I was told it came through the international cord blood bank from somewhere very far away, said Nguyen, who has been in remission since the transplant.

When she learned the stem-cell transplant had been successful, Nguyen, who is now studying to become a pediatric oncology nurse, said it felt too good to be true.

There was a lot of happiness, joy, excitement. Donating cord blood is such a simple way to save a life.

Although cord blood can be collected and stored for a fee by private companies and reserved for the donor familys use, cord blood donated through Canadian Blood Services is available free to the public whoever needs the match.

Wong didnt hesitate when her son was born. I felt like I wanted to do it if it helps someone in the public, and if it could save lives I would have been very happy to help another child, said Wong, who is a nurse at B.C. Womens hospital.

dryan@postmedia.com

CLICK HERE to report a typo.

Is there more to this story? Wed like to hear from you about this or any other stories you think we should know about. Email vantips@postmedia.com.

See the article here:
Chinese New Year babys B.C. family gives gift of life in cord-blood donation - The Province

Bone Marrow Stem Cells Comments Off on Chinese New Year babys B.C. family gives gift of life in cord-blood donation – The Province | February 3rd, 2020

DUBLIN--(BUSINESS WIRE)--The "Stem Cell Banking - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

The global market for Stem Cell Banking is projected to reach US$9.9 billion by 2025, driven by their growing importance in medicine given their potential to regenerate and repair damaged tissue.

Stem cells are defined as cells with the potential to differentiate and develop into different types of cells. Different accessible sources of stem cells include embryonic stem cells, fetal stem cells, peripheral blood stem cells, umbilical cord stem cells, mesenchymal stem cells (bmMSCs) and induced pluripotent stem cells. Benefits of stem cells include ability to reverse diseases like Parkinsons by growing new, healthy and functioning brain cells; heal and regenerate tissues and muscles damaged by heart attack; address genetic defects by introducing normal cells; reduce mortality among patients awaiting donor organs for transplant by regenerating healthy cells and tissues as an alternative to donated organs. While currently valuable in bone marrow transplantation, stem cell therapy holds huge potential in treating a host of common chronic diseases such as diabetes, heart disease (myocardial infarction), Parkinsons disease, spinal cord injury, arthritis, and amyotrophic lateral sclerosis. The technology has the potential to revolutionize public health.

The growing interest in regenerative medicine which involves replacing, engineering or regenerating human cells, tissues or organs, will push up the role of stem cells. Developments in stem cells bioprocessing are important and will be key factor that will influence and help regenerative medicine research move into real-world clinical use. The impact of regenerative medicine on healthcare will be comparable to the impact of antibiotics, vaccines, and monoclonal antibodies in current clinical care. With global regenerative medicine market poised to reach over US$45 billion 2025, demand for stem cells will witness robust growth.

Another emerging application area for stem cells is in drug testing in the pharmaceutical field. New drugs in development can be safely, accurately, and effectively be tested on stem cells before commencing tests on animal and human models. Among the various types of stem cells, umbilical cord stem cells are growing in popularity as they are easy and safe to extract. After birth blood from the umbilical cord is extracted without posing risk either to the mother or the child. As compared to embryonic and fetal stem cells which are saddled with safety and ethical issues, umbilical cord is recovered postnatally and is today an inexpensive and valuable source of multipotent stem cells. Until now discarded as waste material, umbilical cord blood is today acknowledged as a valuable source of blood stem cells. The huge gap between newborns and available cord blood banks reveals huge untapped opportunity for developing and establishing a more effective banking system for making this type of stem cells viable for commercial scale production and supply. Umbilical cord and placenta contain haematopoietic blood stem cells (HSCs). These are the only cells capable of producing immune system cells (red cells, white cells and platelet).

HSCs are valuable in the treatment of blood diseases and successful bone marrow transplants. Also, unlike bone marrow stem cells, umbilical cord blood has the advantage of having 'off-the-shelf' uses as it requires no human leukocyte antigen (HLA) tissue matching. Developments in stem cell preservation will remain crucial for successful stem cell banking. Among the preservation technologies, cryopreservation remains popular. Development of additives for protecting cells from the stresses of freezing and thawing will also be important for the future of the market. The United States and Europe represent large markets worldwide with a combined share of 60.5% of the market. China ranks as the fastest growing market with a CAGR of 10.8% over the analysis period supported by the large and growing network of umbilical cord blood banks in the country. The Chinese government has, over the years, systematically nurtured the growth of umbilical cord blood (UCB) banks under the 'Developmental and Reproductive Research Initiation' program launched in 2008. Several hybrid public-private partnerships and favorable governmental licensing policies today are responsible for the current growth in this market.

Companies Mentioned

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES

CANADA

JAPAN

CHINA

EUROPE

FRANCE

GERMANY

ITALY

UNITED KINGDOM

REST OF EUROPE

ASIA-PACIFIC

REST OF WORLD

IV. COMPETITION

V. CURATED RESEARCH

For more information about this report visit https://www.researchandmarkets.com/r/9b2ra3

See the article here:
Global Stem Cell Banking Market Analysis, Trends, and Forecasts 2019-2025 - ResearchAndMarkets.com - Business Wire

Bone Marrow Stem Cells Comments Off on Global Stem Cell Banking Market Analysis, Trends, and Forecasts 2019-2025 – ResearchAndMarkets.com – Business Wire | February 3rd, 2020

Photo Courtesy of Michael MankowichAbove, Michael Mankowich and his wife, Kathleen, in Patagonia

NUTLEY, NJ When Nutley resident Michael Mankowichs lower back started to bother him, he figured it was a souvenir from his earlier athletic days. Mike, 58, had been a top-notch wrestler at 132 pounds at Long Islands Commack North High School. Hed been an all-American, in fact, as well as a two-time all-Ivy, three-time New York state champ and three-time EIWA tournament placer as a wrestler at Cornell University. An old wrestlers injury was all it was, he figured, a physical reminder of a quick takedown of an opponent 40 years long forgotten.

But the pain did not go away.

Mike began to see a doctor and a chiropractor, and eventually he got an MRI. The news he received at Memorial Sloan Kettering Cancer Center in February 2017 was not good. He was diagnosed with multiple myeloma, a cancer that attacks the blood plasma cells responsible for creating disease-fighting antibodies.

They figured it out quickly at Sloan, he said recently, seated with his wife, Kathleen, in their Rutgers Place home. I kept it from Kathleen.

With this news, he became withdrawn, and his wife realized something was wrong. Mike told her what he had learned, and, as so often happens when a couple puts their heads together, they found some reason for hope: multiple myeloma is a blood disease in the bone marrow and, as such, does not metastasize.

Thats where all the action takes place, in the bone marrow, Mike said. You have to keep your chin up.

For treatment, he became part of a six-month chemotherapy clinical study. Mike was glad to be in the study, because most multiple myeloma patients go on chemotherapy for three months and then undergo a stem-cell transplant. He, however, would not.

A stem-cell transplant blows out the immune system, he said.

Kathleen, an administrative coordinator at Felician University School of Nursing, said her husband, a real estate management employee, did not break stride and never missed the commute to New York City during the clinical study.

A member of Nutley High Schools Class of 1976, Kathleen got on the computer.

When your spouse is diagnosed with an incurable cancer, you do a bit of research, she said.

She discovered the Multiple Myeloma Research Foundation website and learned it was founded 30 years earlier by a woman named Kathy Giusti, who was living with the disease.

That gave me hope, Kathleen said.

She also learned about a collaboration between MMRF and CURE Media Group called Moving Mountains for Multiple Myeloma, or MM4MM.

This collaboration promotes endurance events, undertaken by multiple myeloma patients, to places like Mount Fuji, Mount Kilimanjaro and Iceland. The treks raise money for research, as well as public awareness about the disease. A patient selected to participate in one of these exotic treks had to raise funds, but the trip itself was underwritten by Celgene, a pharmaceutical company headquartered in Summit.

Mike was interested and applied in November 2018 for a spot on a team going to Patagonia. He was interviewed and accepted on condition of raising $10,000 for MMRF research. He suggested that Kathleen accompany him, and they eventually raised $30,000 through social media and by asking friends, family and neighbors.

The online MMRF page devoted to Mikes fundraising shows a photograph of him with his arms around Kathleen and their daughter, Mary, a Class of 2020 NHS student.

In a letter featured on the page, Mike informs the reader that MMRF is one of the worlds leading private funders of myeloma research, with 10 new treatments approved by the Food and Drug Administration.

In August 2019, Mike and Kathleen were flown to Oregon to meet their teammates and to get a taste of what was in store for them in Patagonia. According to the MM4MM website: Each team is carefully selected, representing a microcosm of the myeloma community patients, caregivers, health care professionals and clinical trials managers, as well as representatives from our pharma partners, from CURE Magazine and the MMRF to emphasize the collaboration necessary to drive toward cures.

The foundation sent the group to Mount Hood, Mike said. It was the first time we met. What a great group of people. There were around 15 from all over the country, and there was one other couple, but no one else from New Jersey.

Four other multiple myeloma patients were in the group, he said. he team climbed for nine hours and then headed home.

To prepare for the trip to Patagonia, a region containing part of the Andes mountain range, Mike and Kathleen began a regime of long walks. For instance, theyd walk from Nutley to South Orange and went hiking in New Yorks Harriman State Park.

The MMRF website described the journey as one of arduous adventure: This team will traverse Patagonia crossing over glaciers, through deep valleys, and ascending challenging peaks. This is a powerful and life-changing experience, as the team overcomes challenges, pushes beyond perceived limits and honors loved ones and friends living with multiple myeloma.

For the trek, the team flew to El Calafate, Argentina. As the team embarked on different climbs, documentary filmmakers accompanied them.

The hiking was physically difficult, Mike said. We hiked in rain and incredible winds. In one particular hike, as soon as you felt the winds, you hit the ground. I was surprised nobody got hurt. Some of those slopes were pretty steep. But the scenery was unworldly, and there were condors.

Both Mike and Kathleen agreed that the most memorable sight was La Condorera, which their itinerary described as a nearly vertical massif, offering a home to one of the greatest concentrations of endangered condors in the world. A massif is a group of mountains standing apart from other mountains.

It was a difficult hike, Kathleen said. Youre ready to pass out getting to the top. But its so worth it. The panorama is a view of glaciers and condors. It was spectacular.

Mike and Kathleen returned home on Nov. 16, but there were no goodbyes at the airport. The team had grown so incredibly close that everyone felt they would be seeing each other again, a feeling grounded in the knowledge that multiple myeloma can be challenged and hopefully, one day, defeated.

Our goal in all of this is that you can have multiple myeloma and still do incredible things, Kathleen said.

Its an incentive to other patients to get out there and enjoy their lives, Mike said. And find a cure for multiple myeloma. I have a little bias. I have it.

FEATURED, MOBILE

See the original post here:
Fighting cancer with every step to Patagonia - Essex News Daily

Bone Marrow Stem Cells Comments Off on Fighting cancer with every step to Patagonia – Essex News Daily | February 2nd, 2020

Get Sample Copy Of[emailprotected]https://www.theinsightpartners.com/sample/TIPHE100001334/

The Global Umbilical Cord Blood Banking Market Analysis to 2025 is a specialized and in-depth study of the medical device industry with a focus on the global market trend. The report aims to provide an overview of global umbilical cord blood banking market with detailed market segmentation by product, application, end users, and geography. The global umbilical cord blood banking market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the market.Some of the key players influencing the market are

The report also includes the profiles of key umbilical cord blood banking manufacturing companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, products and services offered, financial information of last 3 years, key development in past five years.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global umbilical cord blood banking market based on product, application, and end users. It also provides market size and forecast till 2025 for overall Umbilical cord blood banking market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 counties globally along with current trend and opportunities prevailing in the region.

North America holds the largest share for umbilical cord blood banking market. This largest share of the region can be attributed to increasing prevalence of chronic diseases and rising awareness about importance of cord blood. However, Asia Pacific is the fastest growing region in the umbilical cord blood banking market over the forecast period. Although the region currently holds a nominal share in the global market, it offers enormous growth potential owing to vast improvement in health care reforms and increasing awareness of stem cell banking in selected countries of Asia Pacific, such as India, China, and Japan.

The report analyzes factors affecting market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the umbilical cord blood banking market in these regions.

Click For More Discount[emailprotected]https://www.theinsightpartners.com/buy/TIPHE100001334/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.

We are committed to providing highest quality research and consulting services to our customers. We help our clients understand key market trends, identify opportunities, and make informed decisions by providing market research solutions at an affordable cost.

Contact us:

The Insight partners,

Phone: +1-646-491-9876

Email:[emailprotected]

Original post:
Umbilical Cord Blood Banking Market 2020 Global Analysis By CBR Systems, Inc., Cordlife., StemCyte India Therapeutics And Others - Dagoretti News

Bone Marrow Stem Cells Comments Off on Umbilical Cord Blood Banking Market 2020 Global Analysis By CBR Systems, Inc., Cordlife., StemCyte India Therapeutics And Others – Dagoretti News | January 31st, 2020

BOSTON, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for APR-246 in combination with azacitidine for the treatment of myelodysplastic syndromes (MDS) with a susceptible TP53 mutation.

MDS represents a spectrum of hematopoietic stem cell malignancies in which bone marrow fails to produce sufficient numbers of healthy blood cells. Approximately 30-40% of MDS patients progress to acute myeloid leukemia (AML) and mutation of the p53 tumor suppressor protein is thought to directly contribute to disease progression and a poor overall prognosis.

Breakthrough Therapy Designation further supports our development program for APR-246 in combination with azacitidine in MDS patients with a TP53 mutation, said Christian S. Schade, Chief Executive Officer of Aprea. Outcomes for MDS patients with a TP53 mutation are poor and there are no current therapeutic options specifically for these patients. We look forward to continued interaction with FDA regarding our ongoing Phase 3 clinical study and our clinical development program to advance APR-246.

The FDAs Breakthrough Therapy Designation is intended to expedite the development and review of a drug candidate that is planned to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies on one or more clinically significant endpoints.

About p53 and APR-246

The p53 tumor suppressor gene is the most frequently mutated gene in human cancer, occurring in approximately 50% of all human tumors. These mutations are often associated with resistance to anti-cancer drugs and poor overall survival, representing a major unmet medical need in the treatment of cancer.

APR-246 is a small molecule that has demonstrated reactivation of mutant and inactivated p53 protein by restoring wild-type p53 conformation and function and thereby induce programmed cell death in human cancer cells. Pre-clinical anti-tumor activity has been observed with APR-246 in a wide variety of solid and hematological cancers, including MDS, AML, and ovarian cancer, among others. Additionally, strong synergy has been seen with both traditional anti-cancer agents, such as chemotherapy, as well as newer mechanism-based anti-cancer drugs and immuno-oncology checkpoint inhibitors. In addition to pre-clinical testing, a Phase 1/2 clinical program with APR-246 has been completed, demonstrating a favorable safety profile and both biological and confirmed clinical responses in hematological malignancies and solid tumors with mutations in the TP53 gene.

A pivotal Phase 3 clinical trial of APR-246 and azacitidine for frontline treatment of TP53 mutant MDS is ongoing. APR-246 has received Orphan Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the EMA for MDS, AML and ovarian cancer.

About Aprea Therapeutics

Aprea Therapeutics Inc., (NASDAQ: APRE) is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein p53. The Companys lead product candidate is APR-246, a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). For more information, please visit the company website at http://www.aprea.com.

The Company may use, and intends to use, its investor relations website at http://www.ir.aprea.com as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements

Certain information contained in this press release includes forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinical trials and regulatory submissions. We may, in some cases use terms such as predicts, believes, potential, continue, anticipates, estimates, expects, plans, intends, may, could, might, likely, will, should or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to the success and timing of our clinical trials or other studies and the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including our Quarterly Report on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Corporate Contacts:

Scott M. CoianteSr. Vice President and Chief Financial Officer617-463-9385

Gregory A. KorbelVice President of Business Development617-463-9385

Source: Aprea Therapeutics, Inc.

More here:
Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic...

Bone Marrow Stem Cells Comments Off on Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic… | January 30th, 2020

The report helps players and investors to stay in a competent position in the global Cell Transplant market as they gain insights into the market competition, leading segments, top regions, and other vital subjects.

The report on the global Cell Transplant market is just the resource that players need to strengthen their overall growth and establish a strong position in their business. It is a compilation of detailed, accurate research studies that provide in-depth analysis on critical subjects of the global Cell Transplant market such as consumption, revenue, sales, production, trends, opportunities, geographic expansion, competition, segmentation, growth drivers, and challenges.

Get the Sample of this [emailprotected]https://www.qyresearch.com/sample-form/form/1495010/global-cell-transplant-market

As part of geographic analysis of the global Cell Transplant market, the report digs deep into the growth of key regions and countries, including but not limited to North America, the US, Europe, the UK, Germany, France, Asia Pacific, China, and the MEA. All of the geographies are comprehensively studied on the basis of share, consumption, production, future growth potential, CAGR, and many other parameters.

Market Segments Covered:

The key players covered in this studyRegen BiopharmaGlobal Cord Blood CorporationCBR SystemsEscape TherapeuticsCryo-SaveLonza GroupPluristem TherapeuticsStemedica Cell Technology

Market segment by Type, the product can be split intoPeripheral Blood Stem Cells Transplant (PBSCT)Bone Marrow Transplant (BMT)Cord Blood Transplant (CBT)

Market segment by Application, split intoHospitalsClinicsOthers

Regions Covered in the Global Cell Transplant Market:

The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Highlights of the Report Accurate market size and CAGR forecasts for the period 2019-2025 Identification and in-depth assessment of growth opportunities in key segments and regions Detailed company profiling of top players of the global Cell Transplant market Exhaustive research on innovation and other trends of the global Cell Transplant market Reliable industry value chain and supply chain analysis Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

The scope of the Report:

The report offers a complete company profiling of leading players competing in the global Cell Transplant market with high focus on share, gross margin, net profit, sales, product portfolio, new applications, recent developments, and several other factors. It also throws light on the vendor landscape to help players become aware of future competitive changes in the global Cell Transplant market.

Get Customized Report in your Inbox within 24 hours @https://www.qyresearch.com/customize-request/form/1495010/global-cell-transplant-market

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Cell Transplant market

Chapter 2: Evaluating the leading manufacturers of the global Cell Transplant market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Cell Transplant market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9 : To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

About Us:QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Continue reading here:
Cell Transplant Market 2020 In Depth Research, Size, Trends and Forecast by 2026 | Regen Biopharma, Global Cord Blood Corporation, CBR Systems -...

Bone Marrow Stem Cells Comments Off on Cell Transplant Market 2020 In Depth Research, Size, Trends and Forecast by 2026 | Regen Biopharma, Global Cord Blood Corporation, CBR Systems -… | January 30th, 2020

A dad who saved the life of a cancer patient 6,600 miles away was flown around the world on a trip of a lifetime by his grateful recipient - who tracked him down.

Milton Becker, 69, was close to death and in desperate need of a bone marrow donor when a two-and-a-half year global search linked him with an anonymous Welsh man.

Emyr Williams, 54, was a near-perfect match, and his bone marrow was flown to Canada and given to Milton, who was declared cancer free.

The pair were linked up by the donation database and grew close via phone calls and Facebook messages.

And last year he invited retired carpenter Emyr to Canada for a two week body">

A dad who saved the life of a cancer patient 6,600 miles away was flown around the world on a trip of a lifetime by his grateful recipient - who tracked him down.

Milton Becker, 69, was close to death and in desperate need of a bone marrow donor when a two-and-a-half year global search linked him with an anonymous Welsh man.

Emyr Williams, 54, was a near-perfect match, and his bone marrow was flown to Canada and given to Milton, who was declared cancer free.

The pair were linked up by the donation database and grew close via phone calls and Facebook messages.

And last year he invited retired carpenter Emyr to Canada for a two week $15,000 (8,835) trip around Alberta and the Rocky Mountains.

Meeting him for the first time at the airport, wearing a Welsh dragon T-shirt and a Wales flag, they formed an instant bond.

Milton said he's "indebted" to his hero - and is planning a UK trip.

Dad-of-three Emyr, from Lampeter, Wales, said: "It was surreal to be out there.

"There's this bond between us like no other.

"It was only when we went out there that we really understood how close to death Milton was.

"One of his friends said he had been finalising plans to be at his funeral.

"He was literally on death's door.

"For something that required no real effort at all saved that great man's life.

"And to have the pleasure of meeting him in the flesh and to be introduced to his family was just an honour."

Granddad-of-two Milton, from Alberta, Canada, added: "We got on so well and I just thought I've got to thank this guy.

"I didn't want him to spend a penny. It was my treat.

"It's not about the money. What he did was priceless.

"I'm forever indebted to the guy."

Milton was diagnosed with stage 4 leukaemia in 2010 but after unsuccessful chemotherapy he was told a bone marrow transplant was the only means of survival.

Doctors searched across Canada but were unsuccessful and begun their two-and-a-half year worldwide search for a donor.

In early 2013, Emyr - who had been registered on the blood transfusion register for several years - was found to be a near-perfect match.

Emyr said: "A lady called me one day to say 'would you be interested in donating your stem cells?

"She went on to say there was a guy in Canada with leukaemia and that I was a 99.9999 per cent match with him.

"I just thought why not.

"It doesn't cost me anything and it can really change somebody's life."

The bone marrow was flown from Wales - with Milton receiving his long-awaited transfusion on his 63rd birthday, on 1st February 2013.

Former oil company lorry driver Milton said: "What he did was completely priceless.

"There's no better gift than the gift of life.

"And to get that on my birthday, well, it was a great feeling!"

A year after the transfusion Milton was told he was on the road to recovery but was kept in remission and monitored by doctors for the next two years.

In 2016, three years after the blood transfusion, Milton was deemed cancer-free.

It led nurses to ask Milton if he would like to know who his donor was - which he accepted straight away.

They got in touch with Emyr - who'd been given bi-annual anonymous updates - who agreed his details could be passed on.

Emyr said: "A few days later I had this call from an international number.

"I remember it as clear as day.

"He phoned me up and said; 'Emyr, my name is Milton and I just want to say how thankful I am'.

"From then on we just hit it off.

"What makes me laugh is he always forgets his Facebook password so he's a complete technophobe.

"We speak through his children on Facebook.

"We mostly speak about our family."

Milton said: "I couldn't turn up the chance to thank the guy who gave me life!

"I started off by thanking him and we had a great chat.

"I told him I would be forever grateful and wanted to keep in touch."

The two then added each other on Facebook and soon became good friends with weekly messages and monthly phone calls.

Then two years later Milton phoned Emyr to ask if he and his family would be interested in flying out to Canada for a two-week holiday.

Emyr said: "He asked me during one of our phone calls.

"I had never been to Canada and thought it would just be great to meet each other face-to-face."

Emyr flew out with his wife and teenage daughter last September 2019 to start the two-week itinerary around Alberta and the Rocky Mountains.

Emyr said: "He was there at the airport with a Welsh dragon on his T-shirt and a Welsh flag.

"You couldn't miss them.

"We have beautiful mountains here in Wales but Canada was just something else.

"It was an absolutely incredible trip.

"He paid for it all.

"We stayed in cabins, had a party with his extended family, we drank, sat by the open fire, and toasted marshmallows."

Milton added: "One Sunday I took him to my church.

"People knew he was coming and the service and to my surprise Emyr got up and told the church about the successful operation.

"There were tears but it was just beautiful."

Now seven years on from the transfusion, the pair say they are thankful to have one another in each other's lives.

The pair still keep regular contact with one another, with Facebook messages, fortnightly phone calls and even FaceTimed each other on Christmas Day.

Emyr said: "They're planning on coming to Wales next year in June or July.

"We'll definitely go back out there again in a few years.

"Even though we're thousands of miles away, we're such great friends."

Milton said: "We still have our chit-chats and I'd love to go over to the UK.

5,000 (8,835) trip around Alberta and the Rocky Mountains.

Meeting him for the first time at the airport, wearing a Welsh dragon T-shirt and a Wales flag, they formed an instant bond.

Milton said he's "indebted" to his hero - and is planning a UK trip.

Dad-of-three Emyr, from Lampeter, Wales, said: "It was surreal to be out there.

"There's this bond between us like no other.

"It was only when we went out there that we really understood how close to death Milton was.

"One of his friends said he had been finalising plans to be at his funeral.

"He was literally on death's door.

"For something that required no real effort at all saved that great man's life.

"And to have the pleasure of meeting him in the flesh and to be introduced to his family was just an honour."

Granddad-of-two Milton, from Alberta, Canada, added: "We got on so well and I just thought I've got to thank this guy.

"I didn't want him to spend a penny. It was my treat.

"It's not about the money. What he did was priceless.

"I'm forever indebted to the guy."

Milton was diagnosed with stage 4 leukaemia in 2010 but after unsuccessful chemotherapy he was told a bone marrow transplant was the only means of survival.

Doctors searched across Canada but were unsuccessful and begun their two-and-a-half year worldwide search for a donor.

In early 2013, Emyr - who had been registered on the blood transfusion register for several years - was found to be a near-perfect match.

Emyr said: "A lady called me one day to say 'would you be interested in donating your stem cells?

"She went on to say there was a guy in Canada with leukaemia and that I was a 99.9999 per cent match with him.

"I just thought why not.

"It doesn't cost me anything and it can really change somebody's life."

The bone marrow was flown from Wales - with Milton receiving his long-awaited transfusion on his 63rd birthday, on 1st February 2013.

Former oil company lorry driver Milton said: "What he did was completely priceless.

"There's no better gift than the gift of life.

"And to get that on my birthday, well, it was a great feeling!"

A year after the transfusion Milton was told he was on the road to recovery but was kept in remission and monitored by doctors for the next two years.

In 2016, three years after the blood transfusion, Milton was deemed cancer-free.

It led nurses to ask Milton if he would like to know who his donor was - which he accepted straight away.

They got in touch with Emyr - who'd been given bi-annual anonymous updates - who agreed his details could be passed on.

Video Unavailable

Click to playTap to play

Play now

Read more from the original source:
Cancer patient flies dad who saved his life 6600 miles away around the world - Birmingham Live

Bone Marrow Stem Cells Comments Off on Cancer patient flies dad who saved his life 6600 miles away around the world – Birmingham Live | January 30th, 2020

ANN ARBORConventional thinking is that bone regeneration is left to a small number of mighty cells called skeletal stem cells, which reside within larger groups of bone marrow stromal cells.

But new findings from the University of Michigan recasts that thinking.

In a recent study, Noriaki Ono, assistant professor at the U-M School of Dentistry, and colleagues report that mature bone marrow stromal cells metamorphosed to perform in ways similar to their bone-healing stem cell cousinsbut only after an injury.

Bone fracture is an emergency for humans and all vertebrates, so the sooner cells start the business of healing damaged boneand the more cells there are to do itthe better.

Our study shows that other cells besides skeletal stem cells can do this job as well, Ono said.

In the mouse study, inert Cxcl12 cells in bone marrow responded to post-injury cellular cues by converting into regenerative cells, much like skeletal stem cells. Normally, the main job of these Cxcl12-expressing cells, widely known as CAR cells, is to secrete cytokines, which help regulate neighboring blood cells. They were recruited for healing only after an injury.

The surprise in our study is that these cells essentially did nothing in terms of making bones, when bones grow longer, Ono said. Its only when bones are injured that these cells start rushing to repair the defect.

This is important because the remarkable regenerative potential of bones is generally attributed to rare skeletal stem cells, Ono says. These new findings raise the possibility that these mighty skeletal stem cells could be generated through the transformation of the more available mature stromal cells.

These mature stromal cells are malleable and readily available throughout life, and could potentially provide an excellent cellular source for bone and tissue regeneration, Ono says.

The study appears in the journal Nature Communications.

More information:

View post:
After a bone injury, shape-shifting cells rush to the rescue - University of Michigan News

Bone Marrow Stem Cells Comments Off on After a bone injury, shape-shifting cells rush to the rescue – University of Michigan News | January 30th, 2020

What are progenitor cells?

Every cell in the human body, and that of other mammals, originates from stem cell precursors. Progenitor cells are descendants of stem cells that then further differentiate to create specialized cell types.There are many types of progenitor cells throughout the human body. Each progenitor cell is only capable of differentiating into cells that belong to the same tissue or organ. Some progenitor cells have one final target cell that they differentiate to, while others have the potential to terminate in more than one cell type.

Stem cells share two qualifying characteristics. Firstly, all stem cells have the potential to differentiate into multiple types of cells. Secondly, stem cells are capable of unlimited self-replication via asymmetric cell division, a process known as self-renewal.There are two broad categories of stem cells found in all mammals. The first are embryonic stem cells. These cells arise from the inner cell mass of the blastocyst in an early-stage embryo. Embryonic stem cells are the blueprint used to create every cell in the body. Because they can be used to create any type of cell, they are known as pluripotent.

The second type of stem cells found in mammals are adult stem cells (or somatic stem cells). Unlike pluripotent embryonic stem cells, adult stem cells are more limited in relation to the type of cells that they become. Unlike embryonic stem cells that could be used to create any cell, adult stem cells are limited to generating cell types within a specific lineage, such as blood cells or cells of the central nervous system. This level of differentiation potential is termed multipotent.

Stem cells create two types of progeny: more stem cells or progenitor cells. All progenitor cells are descendants of stem cells. When it comes to cell differentiation, they fall on the spectrum between stem cells and fully differentiated (mature) cells.

Whilst stem cells have indefinite replication (left) progenitor cells can at most differentiate into multiple types of specialized cell (right).

Function:

Cellular repair or maintenance

Cell Potency:

Multipotent, oligopotent, or unipotent

Self-renewal:

Limited

Origin:

Stem cells

Creates:

Further differentiated cells (either progenitor cells of mature/fully differentiated cells)

Progenitor cells are an intermediary step involved in the creation of mature cells in human tissues and organs, the blood, and the central nervous system.

The human central nervous system (CNS) contains three types of fully differentiated cells: neurons, astrocytes and oligodendrocytes. The latter two are collectively known as glial cells.Every neuron, oligodendrocyte and astrocyte in the CNS evolves from the differentiation of neural progenitor cells (NPCs). NPCs themselves are produced by multipotent neural stem cells (NSCs). Both NPCs and NSCs are termed neural precursor cells.Before the 1990s, it was believed that neurogenesis terminated early in life. More recent studies demonstrate that the brain contains stem cells that are capable of regenerating neurons and glial cells throughout the human lifecycle. These stem cells have only been found in certain brain regions, including the striatum and lateral ventricle.

Hematopoietic progenitor cells (HPCs) are an intermediate cell type in blood cell development. HPCs are immature cells that develop from hematopoietic stem cells, cells that can both self-renew and differentiate into hematopoietic progenitor cells. HPCs eventually differentiate into one of more than ten different types of mature blood cells.Hematopoietic progenitor cells are categorized based upon their cell potency, or their differentiation potential. As blood cells develop, their potency decreases.

First, hematopoietic stem cells differentiate into multipotent progenitor cells. Multipotent progenitor cells are those with the potential to differentiate into a subset of cell types. These cells then differentiate into either the common myeloid progenitor (CMP) or common lymphoid progenitor (CLP). Both CMPs and CLPs are types of oligopotent progenitor cells (progenitor cells that differentiate into only a few cell types).

CMPs and CLPs continue to differentiate along cell lines into lineage-restricted progenitor cells that become final, mature blood cells.Myeloid progenitor cells are precursors to the following types of blood cells:

Lymphoid progenitor cells (also known as lymphoblasts) are precursors to other mature blood cell types, including:

The primary role of progenitor cells is to replace dead or damaged cells. In this way, progenitor cells are necessary for repair after injury and as part of ongoing tissue maintenance. Progenitor cells also replenish blood cells and play a role in embryonic development.

Neural progenitor cells (NPCs) are being explored alongside neural stem cells for their potential to treat diseases of or injury to the central nervous system. A deeper understanding of how these cells function on a cellular and molecular basis is needed to progress from early experimental research to therapeutic use.NPCs are currently utilized in research conducted on CNS disorders, development, cell regeneration and degeneration, neuronal excitability, and therapy screening. When compared to induced pluripotent stem cells, which are cells reprogrammed into a pluripotent state, NPCs can cut down on time in some experiments.Hematopoietic progenitor cells and stem cells are being researched for their capacity to treat blood cell disorders. They are also currently used to help treat patients with a variety of malignant and non-malignant diseases via bone marrow transplants that deliver bone marrow and peripheral blood progenitor cells to patients. These procedures can assist patients in recovering from the damage caused by chemotherapy.Additionally, researchers are examining the potential of using progenitor cells to create a variety of tissues, such as blood vessels, heart valves, and electrically conductive tissue for the cardiovascular system.

View original post here:
What are Progenitor Cells? Exploring Neural, Myeloid and Hematopoietic Progenitor Cells - Technology Networks

Bone Marrow Stem Cells Comments Off on What are Progenitor Cells? Exploring Neural, Myeloid and Hematopoietic Progenitor Cells – Technology Networks | January 28th, 2020

Daratumumab: A Promising Option

Due to promising new data from several big clinical trials, its now believed that daratumumab can benefit patients with multiple myeloma regardless ofwhether theyre eligible to receive a stem cell transplant.

Daratumumab (also known by its brand name, Darzalex), is a type of drug called a targeted monoclonal antibody. It works by binding to a specific protein called CD38, which is found on the surface of multiple myeloma cells. Once the daratumumab attaches to these proteins on the surface of the cells, the bodys immune system identifies the need to attack and kill the multiple myeloma cells.

As Dr. Nina Shah,a hematologist at the University of California San Francisco, explains, patients receiving a stem cell transplant can benefit from the addition of daratumumab to a combination of the drugs Velcade, Revlimid and dexamethasone (a combination that doctors often abbreviate as Dara VRD).

If, on the other hand, a transplant isnt the right course of treatment for you, you may still be able to benefit from daratumumab when its used in whats called the upfront or first-line treatment setting (meaning as the first part of your treatment, before you receive other drugs) when combined withRevlimid and dexamethasone (a combination that doctors often abbreviate as DRD).

If youre not interested in a transplant, or maybe thats not in the works for you at the moment, you may consider daratumumab, Revlimid and dexamethasone, or DRD,' Dr. Shah explains.

One thing thats really gotten a lot of attention is not just three drugs, but four drugs, Dr. Shah says. She explains that a recent clinical trial called GRIFFIN showed that before a stem cell transplant, treatment with daratumumab in combination with Velcade, Revlimid and dexamethasone was more beneficial than treatment with Velcade, Revlimid and dexamethasone alone.

And when patients who received this combination before their transplant, then went on to receive additional daratumumab after their transplant, the benefit was even greater.

Preliminarily, at least, the data seems to indicate that the patients who got four drugs, then went on to a transplant and then got more daratumumab actually did better than the three drugs, Dr. Shah says.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Nina Shah is a hematologist who specializes in the treatment of multiple myeloma, a type of cancer affecting the blood marrow. She treats patients at the Hematology and Blood and Marrow Transplant Clinic. Read More

Daratumumab (also known by its brand name, Darzalex), is a type of drug called a targeted monoclonal antibody. It works by binding to a specific protein called CD38, which is found on the surface of multiple myeloma cells. Once the daratumumab attaches to these proteins on the surface of the cells, the bodys immune system identifies the need to attack and kill the multiple myeloma cells.

If, on the other hand, a transplant isnt the right course of treatment for you, you may still be able to benefit from daratumumab when its used in whats called the upfront or first-line treatment setting (meaning as the first part of your treatment, before you receive other drugs) when combined withRevlimid and dexamethasone (a combination that doctors often abbreviate as DRD).

If youre not interested in a transplant, or maybe thats not in the works for you at the moment, you may consider daratumumab, Revlimid and dexamethasone, or DRD,' Dr. Shah explains.

One thing thats really gotten a lot of attention is not just three drugs, but four drugs, Dr. Shah says. She explains that a recent clinical trial called GRIFFIN showed that before a stem cell transplant, treatment with daratumumab in combination with Velcade, Revlimid and dexamethasone was more beneficial than treatment with Velcade, Revlimid and dexamethasone alone.

And when patients who received this combination before their transplant, then went on to receive additional daratumumab after their transplant, the benefit was even greater.

Preliminarily, at least, the data seems to indicate that the patients who got four drugs, then went on to a transplant and then got more daratumumab actually did better than the three drugs, Dr. Shah says.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Nina Shah is a hematologist who specializes in the treatment of multiple myeloma, a type of cancer affecting the blood marrow. She treats patients at the Hematology and Blood and Marrow Transplant Clinic. Read More

Link:
The Benefit of Adding Daratumumab to Multiple Myeloma Drug Combinations - SurvivorNet

Bone Marrow Stem Cells Comments Off on The Benefit of Adding Daratumumab to Multiple Myeloma Drug Combinations – SurvivorNet | January 28th, 2020

Submerged in liquid nitrogen vapor at a temperature of minus 175 degrees Celsius, hundreds of thousands of stem cells from all over Europe bide their time in large steel barrels on the outskirts of Warsaw.

Present in blood drawn from the umbilical cord of a newborn baby, stem cells can help cure serious blood-related illnesses like leukemias and lymphomas, as well as genetic conditions and immune system deficits.

Polish umbilical cord blood bank PBKM/FamiCord became the industrys leader in Europe after Swiss firm Cryo-Save went bankrupt early last year.

It is also the fifth largest in the world, according to its management, after two companies in the United States, a Chinese firm and one based in Singapore.

Since the first cord blood transplant was performed in France in 1988, the sector has significantly progressed, fuelling hopes.

Health insurance

Mum-of-two Teresa Przeborowska has firsthand experience.

At five years old, her son Michal was diagnosed with lymphoblastic leukemia and needed a bone marrow transplant, the entrepreneur from northern Poland said.

The most compatible donor was his younger sister, Magdalena.

When she was born, her parents had a bag of her cord blood stored at PBKM.

More than three years later, doctors injected his sisters stem cells into Michals bloodstream.

It was not quite enough for Michals needs but nicely supplemented harvested bone marrow.

As a result, Michal, who is nine, is now flourishing, both intellectually and physically, his mum told AFP.

A cord blood transplant has become an alternative to a bone marrow transplant when there is no donor available, with a lower risk of complications.

Stem cells taken from umbilical cord blood are like those taken from bone marrow, capable of producing all blood cells: red cells, platelets and immune system cells.

When used, stem cells are first concentrated, then injected into the patient. Once transfused, they produce new cells of every kind.

At the PBKM laboratory, each container holds up to 10,000 blood bags Safe and secure, they wait to be used in the future, its head, Krzysztof Machaj, said.

The bank holds around 440,000 samples, not including those from Cryo-Save, he said.

If the need arises, the blood will be ready to use without the whole process of looking for a compatible donor and running blood tests, the biologist told AFP.

For families who have paid an initial nearly 600 euros (around P34,000) and then an annual 120 euros (around P7,000) to have the blood taken from their newborns umbilical cords preserved for around 20 years, it is a kind of health insurance promising faster and more effective treatment if illness strikes.

But researchers also warn against unrealistic expectations.

Beauty products

Hematologist Wieslaw Jedrzejczak, a bone marrow pioneer in Poland, describes promoters of the treatment as sellers of hope, who make promises that are either impossible to realize in the near future or downright impossible to realize at all for biological reasons.

He compares them to makers of beauty products who swear their cream will rejuvenate the client by 20 years.

Various research is being done on the possibility of using the stem cells to treat other diseases, notably nervous disorders. But the EuroStemCell scientist network warns that the research is not yet conclusive.

There is a list of almost 80 diseases for which stem cells could prove beneficial, U.S. hematologist Roger Mrowiec, who heads the clinical laboratory of the cord blood program Vitalant in New Jersey, told AFP.

But given the present state of medicine, they are effective only for around a dozen of them, like leukemia or cerebral palsy, he said.

Its not true, as its written sometimes, that we can already use them to fight Parkinsons disease or Alzheimers disease or diabetes.

EuroStemCell also cautions against private blood banks that advertise services to parents suggesting they should pay to freeze their childs cord blood in case its needed later in life.

Studies show it is highly unlikely that the cord blood will ever be used for their child, the network said.

It also pointed out that there could be a risk of the childs cells not being useable anyway without reintroducing the same illness.

Some countries, such as Belgium and France, are cautious and ban the storage of cord blood for private purposes. Most E.U. countries however permit it while imposing strict controls.

Rapid growth

In the early 2000s, Swiss company Cryo-Save enjoyed rapid growth.

Greeks, Hungarians, Italians, Spaniards and Swiss stored blood from their newborns with the company for 20 years on payment of 2,500 euros (around P140,000) upfront.

When the firm was forced to close in early 2019, clients were left wondering where their stem cells would end up.

Under a kind of back-up agreement, the samples of some 250,000 European families were transferred for storage at PBKM.

The Polish firm, founded in 2002 with 2 million zlotys (around P26 million), has also grown quickly.

Present under the FamiCord brand in several countries, PBKM has some 35% of the European market, excluding Cryo-Save assets.

Over the last 15 months, outside investors have contributed 63 million euros to the firm, PBKMs chief executive Jakub Baran told AFP.

But the company has not escaped controversy: the Polityka weekly recently published a critical investigative report on several private clinics that offer what was described as expensive treatment involving stem cells held by PBKM.IB/JB

RELATED STORIES:

2019: The year gene therapy came of age

Landmark trial finds stem cell treatment reduces disability for those with multiple sclerosis

View original post here:
Europe's guardian of stem cells and hopes, real and unrealistic - INQUIRER.net

Bone Marrow Stem Cells Comments Off on Europe’s guardian of stem cells and hopes, real and unrealistic – INQUIRER.net | January 27th, 2020

Global Cell Therapy Technologies Marketwas valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/31531

Global Cell Therapy Technologies Market: OverviewCell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

Global Cell Therapy Technologies Market: Drivers and RestraintsThe growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation AnalysisOn the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional AnalysisNorth America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/31531

Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & SoftwareGlobal Cell Therapy Technologies Market, by Cell Type

Human Cells Animal CellsGlobal Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality ControlGlobal Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research InstitutesGlobal Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South America

Key players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at:https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

See the original post:
Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2018-2026) - Expedition 99

Bone Marrow Stem Cells Comments Off on Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2018-2026) – Expedition 99 | January 27th, 2020

UCLA Broad Stem Cell Research Center/Nature Medicine

At left, image shows white blood cells (red) from one of the X-CGD clinical trial participants before gene therapy. At right, after gene therapy, white blood cells from the same patient show the presence of the chemicals (blue) needed to attack and destroy bacteria and fungus.

UCLA researchers are part of an international team that reported the use of a stem cell gene therapy to treat nine people with the rare, inherited blood disease known as X-linked chronic granulomatous disease, or X-CGD. Six of those patients are now in remission and have stopped other treatments. Before now, people with X-CGD which causes recurrent infections, prolonged hospitalizations for treatment, and a shortened lifespan had to rely on bone marrow donations for a chance at remission.

With this gene therapy, you can use a patients own stem cells instead of donor cells for a transplant, said Dr. Donald Kohn, a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA and a senior author of the new paper, published today in the journal Nature Medicine. This means the cells are perfectly matched to the patient and it should be a much safer transplant, without the risks of rejection.

People with chronic granulomatous disease, or CGD, have a genetic mutation in one of five genes that help white blood cells attack and destroy bacteria and fungus using a burst of chemicals. Without this defensive chemical burst, patients with the disease are much more susceptible to infections than most people. The infections can be severe to life-threatening, including infections of the skin or bone and abscesses in organs such as lungs, liver or brain. The most common form of CGD is a subtype called X-CGD, which affects only males and is caused by a mutation in a gene found on the X-chromosome.

Other than treating infections as they occur and taking rotating courses of preventive antibiotics, the only treatment option for people with CGD is to receive a bone marrow transplant from a healthy matched donor. Bone marrow contains stem cells called hematopoietic, or blood-forming, stem cells, which produce white blood cells. Bone marrow from a healthy donor can produce functioning white blood cells that effectively ward off infection. But it can be difficult to identify a healthy matched bone marrow donor and the recovery from the transplant can have complications such as graft versus host disease, and risks of infection and transplant rejection.

Patients can certainly get better with these bone marrow transplants, but it requires finding a matched donor and even with a match, there are risks, Kohn said. Patients must take anti-rejection drugs for six to 12 months so that their bodies dont attack the foreign bone marrow.

In the new approach, Kohn teamed up with collaborators at the United Kingdoms National Health Service, France-based Genethon, the U.S. National Institute of Allergy and Infectious Diseases at the National Institutes of Health, and Boston Childrens Hospital. The researchers removed hematopoietic stem cells from X-CGD patients and modified the cells in the laboratory to correct the genetic mutation. Then, the patients own genetically modified stem cells now healthy and able to produce white blood cells that can make the immune-boosting burst of chemicals were transplanted back into their own bodies. While the approach is new in X-CGD, Kohn previously pioneered a similar stem cell gene therapy to effectively cure a form of severe combined immune deficiency (also known as bubble baby disease) in more than 50 babies.

The viral delivery system for the X-CGD gene therapy was developed and fine-tuned by Professor Adrian Thrashers team at Great Ormond Street Hospital, or GOSH, in London, who collaborated with Kohn. The patients ranged in age from 2 to 27 years old; four were treated at GOSH and five were treated in the U.S., including one patient at UCLA Health.

Two people in the new study died within three months of receiving the treatment due to severe infections that they had already been battling before gene therapy. The seven surviving patients were followed for 12 to 36 months after receiving the stem cell gene therapy. All remained free of new CGD-related infections, and six of the seven have been able to discontinue their usual preventive antibiotics.

None of the patients had complications that you might normally see from donor cells and the results were as good as youd get from a donor transplant or better, Kohn said.

An additional four patients have been treated since the new paper was written; all are currently free of new CGD-related infections and no complications have arisen.

Orchard Therapeutics, a biotechnology company of which Kohn is a scientific co-founder, acquired the rights to the X-CGD investigational gene therapy from Genethon. Orchard will work with regulators in the U.S. and Europe to carry out a larger clinical trial to further study this innovative treatment. The aim is to apply for regulatory approval to make the treatment commercially available, Kohn said.

Kohn and his colleagues plan to develop similar treatments for the other forms of CGD caused by four other genetic mutations that affect the same immune function as X-CGD.

Beyond CGD, there are also other diseases caused by proteins missing in white blood cells that could be treated in similar ways, Kohn said.

The research was supported by grants from the California Institute for Regenerative Medicine; the National Heart, Lung and Blood Institute and the National Institute of Allergy and Infectious Diseases, both at the National Institutes of Health; the Wellcome Trust; Boston Childrens Hospital; the National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre; the Institute for Health Research Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London; the Great Ormond Street Hospital Childrens Charity; the AFM-Tlthon, French Muscular Dystrophy Association; and the European Commission through the Net4CGDconsortium.

See the rest here:
Six patients with rare blood disease are doing well after gene therapy clinical trial - Mirage News

Bone Marrow Stem Cells Comments Off on Six patients with rare blood disease are doing well after gene therapy clinical trial – Mirage News | January 27th, 2020

(MENAFN - Gulf Times) The Foot and Ankle sub-specialty at Hamad General Hospital (HGH), part of Hamad Medical Corporation (HMC), will soon introduce the latest medical procedure, BMAC, to treat various illnesses related to foot and ankle.'Bone marrow aspirate concentrate (BMAC) is a regenerative therapy procedure that uses stem cells from a patient's bone marrow to initiate healing for a number of orthopaedic conditions, such as tendinopathy, osteoarthritis and cartilage injuries, said Dr Mohamed Maged Mekhaimar, senior consultant and orthopaedic surgeon at HGH.'This will help treating patients with tendon inflation. It can also be used to treat inflammation on the bottom of the foot as well as for traumatic conditions of the ankle. These services will soon be available at Hamad General Hospital, explained Dr Mekhaimar.Foot and ankle services were started at HGH in 2012. 'Now, there is a great demand for these services in the country as more and more people are approaching us for various issues. The centre provides treatment for several problems such as flat foot problems, among other issues. We also provide treatment for diabetic foot people, he continued.The centre currently performs about five surgeries per day and takes care for all different injuries, including sport injuries.According to the official, the centre also makes use of PRP (Platelet Rich Plasma) machine by which blood is taken from people and then separated. 'Using the PRP machine, we can inject the blood particles to the joints. This facility is available in HGH and the Bone and Joint Center, part of HMC, he noted.'Our clinics are at the Bone and Joint Center. All our patients come through the Bone and Joint Center. We are also in the process of introducing the weight-bearing CT scan machine. With this, we can scan the foot and ankle of the patient while he or she is standing on it. This can give better impression of the condition of the patients, he highlighted.'Some deformity can be better measured through this CT scan machine. It will also be used for treating the knee joint as it is one of the most advanced treatment options available now, he added.

MENAFN2501202000670000ID1099602239

Go here to read the rest:
Qatar- HMC to introduce regenerative therapy to treat foot and ankle illnesses - MENAFN.COM

Bone Marrow Stem Cells Comments Off on Qatar- HMC to introduce regenerative therapy to treat foot and ankle illnesses – MENAFN.COM | January 26th, 2020

Many folks all over the world will be seen troubled by ache within the veins. And many occasions, even after an excessive amount of therapy, this ache shouldnt be relieved. But within the coming days youll be able to do away with neuralgia utterly, that too with none unwanted side effects. Researchers on the University of Sydney have used human stem cells for excessive ache reduction in mice. Now, theyre shifting in the direction of human trials.

Greg Nelly, senior researcher on the Charles Perkins Center, stated that at occasions, extreme stress on the nerves causes them to get broken. For instance, carpal tunnel syndrome is the median nerve within the fingers ( median nerve ) Due to extreme stress.

->As youll be able to think about, nerve accidents can result in insufferable neuropathic ache. There can also be no efficient therapy to alleviate ache in most sufferers.

Therefore, Nelly and colleagues on the University of Sydney developed an efficient remedy. Researchers have been in a position to create pain-relieving neurons utilizing human stem cells.

Nelly stated that this success implies that for some sufferers affected by nerve ache, we are able to carry out pain-relieving implants from our cells, which might cease the ache.

In the research, researchers collected stem cells from grownup blood samples. Then, used human-induced pluripotent stem cells (iPSCs) from the bone marrow to create pain-relieving cells within the laboratory.

To check the efficacy of the therapy, the group injected neurons that abolished spinal ache in mice affected by extreme neuropathic ache. It was revealed that this therapy supplied full reduction from ache to the mice with none unwanted side effects.

Co-senior creator Dr. Leslie Caron stated that because of this transplant remedy is prone to be an efficient and long-lasting therapy for neuropathic ache.

After shut therapy in mice, the University of Sydney group is shifting ahead for extra intensive research in pigs. Within the following 5 years, theyll check people who are suffering from power ache.

Researchers stated {that a} move check in people will probably be a giant success. This could point out the event of latest non-opioid, non-addictive ache administration methods for sufferers.

More:
If youre troubled by ache within the nerves, comply with the following tips, know - Sahiwal Tv

Bone Marrow Stem Cells Comments Off on If youre troubled by ache within the nerves, comply with the following tips, know – Sahiwal Tv | January 26th, 2020

The blood collected from the umbilical cord of the newborn is a rich source of stem cells. This blood is collected and sent to a cord blood bank, where the stem cells are separated, tested, processed, and preserved in liquid nitrogen. Technically, there is no expiry date and these stem cells can be preserved for a lifetime. Scientifically, evidence exists that they can be stored for about 20 years. The stem cells can treat around 70 blood related disorders and genetic disorders including thalassemia, sickle cell anaemia, leukaemia, and immune related disorders.

Stem cells taken from umbilical cord blood are like those taken from bone marrow, capable of producing all blood cells: red cells, platelets and immune system cells. When used, stem cells are first concentrated, then injected into the patient. Once transfused, they produce new cells of every kind.

They're capable of producing all types of blood cells: red cells, platelets and immune system cells. The stem cells can treat around 80 blood related illnesses like leukaemia, lymphomas, several genetic conditions and immune related disorders. But given the present state of medicine, they are effective only for around a dozen of them

See the article here:
Watch | Stem cell banking and its benefits - The Hindu

Bone Marrow Stem Cells Comments Off on Watch | Stem cell banking and its benefits – The Hindu | January 25th, 2020

Poland has emerged as Europe's leader in stem cell storage, a billion-dollar global industry that is a key part of a therapy that can treat leukaemias but raises excessive hopes.

Submerged in liquid nitrogen vapour at a temperature of minus 175 degrees Celsius, hundreds of thousands of stem cells from all over Europe bide their time in large steel barrels on the outskirts of Warsaw.

Present in blood drawn from the umbilical cord of a newborn baby, stem cells can help cure serious blood-related illnesses like leukaemias and lymphomas, as well as genetic conditions and immune system deficits.

Polish umbilical cord blood bank PBKM/FamiCord became the industry's leader in Europe after Swiss firm Cryo-Save went bankrupt early last year.

It is also the fifth largest in the world, according to its management, after two companies in the United States, a Chinese firm and one based in Singapore.

Since the first cord blood transplant was performed in France in 1988, the sector has significantly progressed, fuelling hopes.

- Health insurance -

Mum-of-two Teresa Przeborowska has firsthand experience.

At five years old, her son Michal was diagnosed with lymphoblastic leukaemia and needed a bone marrow transplant, the entrepreneur from northern Poland said.

The most compatible donor was his younger sister, Magdalena.

When she was born, her parents had a bag of her cord blood stored at PBKM.

More than three years later, doctors injected his sister's stem cells into Michal's bloodstream.

It was not quite enough for Michal's needs but nicely supplemented harvested bone marrow.

As a result, Michal, who is nine, "is now flourishing, both intellectually and physically," his mum told AFP.

A cord blood transplant has become an alternative to a bone marrow transplant when there is no donor available, with a lower risk of complications.

Stem cells taken from umbilical cord blood are like those taken from bone marrow, capable of producing all blood cells: red cells, platelets and immune system cells.

Story continues

When used, stem cells are first concentrated, then injected into the patient. Once transfused, they produce new cells of every kind.

At the PBKM laboratory, "each container holds up to 10,000 blood bags... Safe and secure, they wait to be used in the future," its head, Krzysztof Machaj, said.

The bank holds around 440,000 samples, not including those from Cryo-Save, he said.

If the need arises, the "blood will be ready to use without the whole process of looking for a compatible donor and running blood tests," the biologist told AFP.

For families who have paid an initial nearly 600 euros ($675) and then an annual 120 euros to have the blood taken from their newborns' umbilical cords preserved for around 20 years, it is a kind of health insurance promising faster and more effective treatment if illness strikes.

But researchers also warn against unrealistic expectations.

- Beauty products -

Haematologist Wieslaw Jedrzejczak, a bone marrow pioneer in Poland, describes promoters of the treatment as "sellers of hope", who "make promises that are either impossible to realise in the near future or downright impossible to realise at all for biological reasons."

He compares them to makers of beauty products who "swear their cream will rejuvenate the client by 20 years."

Various research is being done on the possibility of using the stem cells to treat other diseases, notably nervous disorders. But the EuroStemCell scientist network warns that the research is not yet conclusive.

"There is a list of almost 80 diseases for which stem cells could prove beneficial," US haematologist Roger Mrowiec, who heads the clinical laboratory of the cord blood programme Vitalant in New Jersey, told AFP.

"But given the present state of medicine, they are effective only for around a dozen of them, like leukaemia or cerebral palsy," he said.

"It's not true, as it's written sometimes, that we can already use them to fight Parkinson's disease or Alzheimer's disease or diabetes."

EuroStemCell also cautions against private blood banks that "advertise services to parents suggesting they should pay to freeze their child's cord blood... in case it's needed later in life."

"Studies show it is highly unlikely that the cord blood will ever be used for their child," the network said.

It also pointed out that there could be a risk of the child's cells not being useable anyway without reintroducing the same illness.

Some countries, such as Belgium and France, are cautious and ban the storage of cord blood for private purposes. Most EU countries however permit it while imposing strict controls.

- Rapid growth -

In the early 2000s, Swiss company Cryo-Save enjoyed rapid growth.

Greeks, Hungarians, Italians, Spaniards and Swiss stored blood from their newborns with the company for 20 years on payment of 2,500 euros upfront.

When the firm was forced to close in early 2019, clients were left wondering where their stem cells would end up.

Under a kind of back-up agreement, the samples of some 250,000 European families were transferred for storage at PBKM.

The Polish firm, founded in 2002 with two million zlotys (around 450,000 euros, $525,000), has also grown quickly.

Present under the FamiCord brand in several countries, PBKM has some 35 percent of the European market, excluding Cryo-Save assets.

Over the last 15 months, outside investors have contributed 63 million euros to the firm, PBKM's chief executive Jakub Baran told AFP.

But the company has not escaped controversy: the Polityka weekly recently published a critical investigative report on several private clinics that offer what was described as expensive treatment involving stem cells held by PBKM.

Read the original here:
Europe's guardian of stem cells and hopes, real and unrealistic - Yahoo News

Bone Marrow Stem Cells Comments Off on Europe’s guardian of stem cells and hopes, real and unrealistic – Yahoo News | January 25th, 2020